Novo Nordisk to cap insulin prices in Minnesota settlement

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Attorney General secures $35 Novo Nordisk insulin for Minnesotans
The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.
Novo Norodisk caps insulin prices at $35 for Minnesotans
Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Settlement secures $35-per-month insulin for all Minnesotans
The final settlement has been reached in the state's 2018 lawsuit filed against the three largest insulin manufacturers.
All Minnesotans can now get insulin for just $35 a month
All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years. State Attorney General Keith Ellison says that’s the result of a settlement announced Monday with Novo Nordisk.

Novo Nordisk’s Ozempic Gets FDA Approval

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
UBS Remains a Buy on Novo Nordisk (0QIU)
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Why Novo Nordisk A/S (NVO) Surged on Friday
We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...
24/7 Wall St11d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk's SWOT analysis: obesity drug leader faces supply hurdles
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...